Definium Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Definium Therapeutics, Inc. (DFTX) reported Deferred Income Tax Expense (Benefit) of -$1.16 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-03-09
- Definium Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2021 was -$1.16M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | -$1.16M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |